which results in a decrease of hematocrit of about 3% to 5% between gestational weeks 20 and 30 2 without substantial accompanying changes in mean corpuscular volume and hemoglobin content of the red blood cells. 3 In large European studies, the majority of pregnant women with normal maternal and fetal outcomes had a range of hemoglobin concentrations during the first and second trimester distinctly lower than that of nonpregnant women. A prospective trial from the northwest Thames region of London found the lowest perinatal mortality among 222 614 women with their first singleton pregnancies, who had the lowest recorded maternal hemoglobin concentration at the first antenatal check-between 9.0 and 11.0 g/dL. 4 In another large British population-based study that included 153 602 pregnant women, babies born to women who had hemoglobin values between 8.5 O ver the past years, only anemia has been recognized as a risk factor for poor fetal outcome, whereas high hemoglobin concentrations have been considered optimal for pregnancy development. Meanwhile, it is well established that between the second trimester and the middle of the third trimester of pregnancy, plasma volume expands by 25% to 80% of prepregnancy volumes. 1 The increase in red cell mass is restricted to about 30%, Summary: Both anemia and the lack of physiological maternal plasma volume expansion during the second trimester are associated with higher maternal morbidity and poor fetal outcome. Mean hemoglobin levels between the 14th and 30th gestational weeks were calculated in 4985 consecutive pregnant women and were correlated with outcome data of pregnancy. It was found that 9.4% of participants (n = 3959) had normal pregnancy outcome. Mean maternal hemoglobin levels were significantly lower in women with a normal pregnancy (11.96 ± 0.94 g/dL) compared with women who had adverse outcome events (preeclampsia, n = 423, 12.5 ± 1.0 g/dL, P < .0001; early birth, n = 464, 12.2 ± 1.01 g/dL, P < .0001; low birth weight newborn, n = 473, 12.2 ± 1.10 g/dL, P < .0001; intrauterine growth retardation, n = 250, 12.2 ± 1.0 g/dL, P < .0001). The risk for any adverse outcome event was lowest with a mean hemoglobin between 11.0 and 12.0 g/dL (odds ratio, 0.625; 95% confidence interval, 0.43-0.89) and highest between 13.0 and 15.0 g/dL (odds ratio, 2.24; 95% confidence interval, 1.54-3.31). In this population-based study from a community in Western Germany, impaired plasma volume expansion was an independent risk factor for the development of an adverse outcome of pregnancy.
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Patients And Methods

Pregnant Women
From January 1990 to the end of December 1996, 4985 consecutive women with singleton pregnancy who delivered in our department were eligible to be included in this retrospective investigation. To assess the maternal data, we photocopied the maternity records (Mutterpass). These records include information on previous pregnancies and deliveries and the current pregnancy (eg, results of routine physical examination and ultrasound fetometry documented by the external obstetrician), in addition to systolic and diastolic blood pressures, hemoglobin concentrations, and urine and immunologic/hematologic results. Moreover, the personal, medical, and social histories with particular emphasis on risk factors of pregnancy and delivery such as obesity, smoking, comorbidity, and drug use are documented. To determine mean hemoglobin concentrations during the second trimester, values between the 14 th and 30 th weeks of gestation were adopted and calculated from the maternity records. The following maternal and fetal data were assessed: geographic origin, birth weight, week of gestation at the time of delivery, small-for-date newborns (in the absence of congenital malformations or chromosomal abnormalities), the presence and type of preeclampsia (hemolysis, elevated liver enzymes, low platelet syndrome), abruptio placentae, fetal death and perinatal mortality, venous pH in the umbilical cord, and 1-minute, 5-minite, and 10-minute Apgar scores.
To stratify normal and abnormal, we defined the terms similarly for all subjects:
• Low birth weight: <2500 g • Early birth: <37 weeks of gestation • Intrauterine growth retardation (IUGR): <5th percentile • Preeclampsia: blood pressure (BP) 140/90 and proteinuria >300 mg/24 hours
Data Collection
The obstetrics department is linked to the perinatal registration of Hessen. This is a central institution that administers all data on deliveries each year for statistical evaluation. Participating hospitals record information on pregnancy, delivery, and fetal outcome of the women who deliver in their department by means of a standardized and computerized protocol. Additionally, in a supplementary protocol we also record clinical and laboratory results obtained at the time of admission for delivery, which include duplex and ultrasound, blood pressure, urinary status, cardiotocography, hematology, and blood rheology of the fetus and the mother during delivery and at the time of discharge. The merge of both protocols enables a combined evaluation of clinical findings and blood test results of more than 200 variables. Data were computerized using a program produced by the authors and converted for statistical evaluation.
Statistical Analysis
Descriptive analysis included mean value ± standard deviation, median, interquartile range, and 95% confidence interval (CI). Differences between groups were assessed with Wilcoxon's test for unpaired samples and tested against zero. Fisher's exact test (two tailed) and risk ratios were used to compare incidences in the two groups. Correlation coefficients according to Spearman were calculated. Two-sided P values of less than .05 were considered to represent statistical significance. Variables were tested univariately by logistic regression analysis for possible prediction of adverse outcome events. Only variables with P < .05 were selected as possibly predictive of adverse pregnancy outcome events and were entered in a stepwise logistic regression analysis (multivariate analysis). Odds ratios (ORs) together with the 95% CIs were calculated. Receiver operating characteristic (ROC) curves were built to describe the observed sensitivity and specificity of ranked mean second trimester hemoglobin concentrations for the prediction of adverse outcome events. The area under the resulting ROC curve (AUC) was then calculated. Statistical analyses were conducted in collaboration with the Institute for Medical Biometrics, Epidemiology and Informatic of the University of Mainz. The statistical analysis was performed using the SAS 9.1 program package (SAS Institute, Berkley, Calif).
Results
Patients Studied
During the observation time, 5035 consecutive Caucasian women delivered in the department, of whom 50 nonsingleton pregnant women were excluded from calculation. We found that 79.4% (n = 3,959) had normal pregnancy outcome, 8.4% (n = 423) developed preeclampsia, 9.5% (n = 473) delivered a low birth weight newborn, 9.3% (n = 464) had early birth, and 5.0% (n = 250) were diagnosed with IUGR. In patients with preeclampsia, the prevalence of classical risk factors was significantly higher such as older age, higher body mass index (BMI) and increased weight gain during pregnancy, and status as a smoker compared with women who had normal pregnancy outcome. By contrast, women with a diagnosis of IUGR and women who delivered a low birth weight baby had significantly lower weight before pregnancy and significantly less weight gain during pregnancy, whereas the relative number of smokers was higher compared with that among women with normal pregnancy outcome ( Table 1 ). The number of patients receiving iron supplement during pregnancy was not significantly different among women with normal pregnancy (n = 334; 8.5%), preeclampsia (n = 24; 5.7%; P = .05), low birth weight babies (n = 35; 7.4%; P = .48), early birth (n = 32; 6.9%; P = .28), and IUGR (n = 24; 9.6%; P = .29). Women with a complicated pregnancy had significantly lower mean gestational age at the time of delivery than those with normal pregnancy. The number of female newborns was significantly higher among those with low birth weight babies and a diagnosis of IUGR compared with those who had normal pregnancy outcome. Table 2 compares fetal outcome results in women with normal versus complicated pregnancies.
Maternal Hemoglobin Concentration During the Second Trimester
During the second trimester, 34 895 hemoglobin estimations were included in the calculations. The [8] ; P = 0.82), but patients who delivered a low birth weight baby (6.6 ± 2.9 [6] ; P < .0001), had early birth (6.5 ± 2.9 [6] ; P < .0001), or had IUGR (6.8 ± 2.5 [6] ; P < .0001) had hemoglobin estimations less often. Hemoglobin was lower in pregnant women with normal outcome (mean ± SD: 11.9 ± 0.9 g/dL) compared with women who had adverse outcome events (mean 12.1-12.5 g/dL; P < .0001; Fig. 1 ). Distribution of mean hemoglobin values at this time followed a bell-shaped pattern in all pregnancies and was disposed to the right in patients with complicated outcome. Ninety percent of women with normal outcome had values below 13.0 g/dL, whereas 33.0% of patients with subsequent preeclampsia, 24% with IUGR, and 20% who delivered a low birth weight baby or had early birth had values above 13.0 g/dL. According to the distribution categories of the hemoglobin used in Figure  2 , relative risk for the development of complicated pregnancy was lowest, with a mean second trimester hemoglobin value between 11.0 g/dL and 12. 3 .41, 95% CI, 2.84-4.09). Altogether, the rate of complicated and normal pregnancies was not significantly different within other ranges of the hemoglobin (OR, ~1.0; P > .05). Less than 5% of patients with preeclampsia had hemoglobin values below 11.0 g/dL and 1.5% had values below 10.0 g/dL compared with 18.0% and 3.0% of the women with normal pregnancies, respectively. ROC curves were plotted for the prediction of mean second trimester hemoglobin concentrations and the development of adverse outcome events. AUC was highest in preeclampsia (0.683; 95% CI, 0.656-0.711), and as shown in Figure 3 , a mean second trimester value of 12.1 g/dL had optimal sensitivity (70%) and specificity (41%). The AUC for other adverse outcome events was between 0.58 (low birth weight) and 0.60 (IUGR).
Second trimester hemoglobin concentration was not correlated with maternal age (r = 0.04; P = .003), maternal BMI (r = 0.08; P < .0001), gain of maternal weight during pregnancy (r = 0.04; P = .004), gestational age at delivery (r = -0.06; P = .007), and newborn birth weight (r = -0.07; P < .0001). The number of women with severe anemia (hemoglobin <7.0 g/dL) was small (n = 4), but none of the women with a mean hemoglobin concentration below 9.0 g/dL experienced adverse outcome events during pregnancy.
Logistic Regression for the Development of Adverse Outcome Events During Pregnancy
Odds ratios and 95% CIs were calculated for women with complicated and normal pregnancies including variables such as maternal age, BMI, weight before pregnancy, weight gain during pregnancy, smoking habit, presence of proteinuria (>300 mg/24 h), increased diastolic or systolic maternal blood pressure (BP systolic >140 mm Hg and/or BP diastolic >90 mm Hg), and mean maternal hemoglobin concentration during the second trimester. Variables were treated as continuous. All tested variables except smoking and the number of consumed cigarettes per day were significant risk factors for the occurrence of preeclampsia (Fig. 4A) . When entered in a multivariate analysis, mean maternal second trimester hemoglobin (OR, 1.48; 95% CI, 1.291-1.699; P < .0001), mean second trimester systolic BP (OR, 5.854; 95% CI, 4.285-7.996; P < .0001), mean second trimester diastolic BP (OR, 7.672; 95% CI, 5.608-10.496; P < .0001), maternal age (OR, 1.033; 95% CI, 1.008-1.058; P = .009), and proteinuria during second trimester (OR, 1.372; 95% CI, 1.058-1.780; P = .01) were statistically significant independent prognostic markers for the development of preeclampsia.
In the univariate analysis, increasing mean maternal hemoglobin concentration during the second trimester, pathological BP at that time, status as a smoker, the number of cigarettes per day, maternal age, and a lower maternal weight before pregnancy were statistically significant risk factors for delivery of a low birth weight newborn (Fig. 4B) . In the multivariate calculations, mean maternal second trimester hemoglobin (OR, 1.241; 95% CI, 1.166-1.381; P < .0001), mean second trimester systolic BP (OR, 2.2; 95% CI, 1.557-3.107; P < .0001), mean second trimester diastolic BP (OR, 3.451; 95% CI, 2.437-4.888; P < .0001), weight before pregnancy (OR, 0.966; , weight before pregnancy, weight gain during pregnancy, smoking habit, presence of proteinuria (>300 mg/24 hours), increased diastolic and systolic maternal blood pressures (>140 and/or >90 mm Hg, respectively), and mean maternal hemoglobin concentration during the second trimester (II trim.). Variables were treated as continuous (box plots, 95% confidence interval; lines, odds ratios). RR, blood pressure.
95% CI, 0.951-0.984; P < .0001), maternal age (OR, 1.044; 95% CI, 1.005-1.024; P = .005), and smoking (OR, 1.748; 95% CI, 1.177-2.597; P = .006) were statistically significant independent prognostic markers for the delivery of low birth weight children.
The risk for delivery of a growth-retarded newborn was significantly associated with increasing mean maternal hemoglobin concentration and pathological BP during the second trimester, smoking, the number of cigarettes per day, and a lower weight before pregnancy (Fig. 4C) . Mean maternal second trimester hemoglobin (OR, 1.352; 95% CI, 1.175-1.556; P < .0001), weight before pregnancy (OR, 0.967; 95% CI, 0.955-0.979; P < .0001), mean second trimester diastolic BP (OR, 2.790; 95% CI, 1.769-4.402; P < .0001), smoking (OR, 2.216; 95% CI, 1.381-3.558; P = .001), and mean second trimester systolic BP (OR, 2.138; 95% CI, 1.366-3.346; P = .003) were statistically significant independent prognostic markers for delivery of a growth-retarded child.
Increasing mean hemoglobin concentration, a pathological BP during the second trimester, smoking, and maternal age were significant risk factors for early birth according to the univariate analysis ( Fig. 4D ). An older maternal age (OR, 1.039; 95% CI, 1.020-1.058; P < .0001), mean second trimester diastolic BP (OR, 2.729; 95% CI, 1.929-3.862; P < .0001), mean second trimester hemoglobin (OR, 1.210; 95% CI, 1.087-1.347; P = .0005), mean second trimester systolic BP (OR, 1.831; 95% CI, 1.297-2.585; P = .0006), and the number of cigarettes per day (OR, 1.032; 95% CI, 1.004-1.361; P = .03) were independent prognostic markers.
Discussion
In a number of large and well-designed trials, a high hemoglobin concentration early during pregnancy was followed by a higher rate of adverse outcome events, such as stillbirth, 14, 15 early birth, 16, 17 delivery of a growth-retarded infant, 7, 8, 16 delivery of a low-weight newborn, 5, 9, 11, 12 or preeclampsia. 7, 8, 16 Rasmussen and Olan 9 found an independent inverse correlation between second trimester hemoglobin values and fetal birth weight as well as a strong positive correlation between first to second trimester decreases in hemoglobin and fetal birth weight. In a retrospective trial of 54 382 singleton pregnancies, perinatal mortality and the incidence of low birth weight newborns as well as early birth deliveries were strikingly higher in women whose hemoglobin concentrations at 13 to 19 weeks of gestation were greater than 13.2 g/dL compared with those who had a value between 10.4 and 13.2 g/dL. Forty-two percent of primiparae women with hemoglobin values greater than 14.5 g/dL had hypertensive disorders, a number that was significantly higher than the 7% incidence found in women who had mean second trimester hemoglobin values less than 10.5 g/dL (P < .001). 7 Based on more than 34 800 hemoglobin estimations from 4985 consecutive women with singleton pregnancies, women with adverse outcome events (namely preeclampsia, IUGR, early birth, or delivery of a low weight newborn) had significantly higher mean hemoglobin concentrations during the second trimester compared with women whose pregnancy remained uneventful. The risk of development of each adverse outcome event increased with a rising mean hemoglobin concentration. Moreover, mean hemoglobin value during the second trimester was an independent prognostic marker for subsequent diagnosis of all 4 adverse outcome events. At this time, the highest mean hemoglobin concentrations were calculated in patients with subsequent preeclampsia. Mean hemoglobin concentrations were independent of maternal age, BMI, or smoking habit of women. Subgroup analysis revealed no correlation between high hemoglobin and pathological blood pressure, proteinuria, or gestational age at term in a complicated pregnancy.
The link between a high hemoglobin concentration early during pregnancy and the development of a complicated pregnancy is unclear. A high hemoglobin concentration during the second trimester may be a symptom of ineffective plasma volume expansion 18 or the result of increased erythropoiesis attributable to a compensatory mechanism caused by impaired oxygenation in the placenta 19 and/or the release of placental factors that promote erythropoiesis, such as activin A. 20 This may have a profound effect on the maintenance of the uteroplacental circulation, 21 because concentrations are positively correlated with perivillous fibrin deposition and placental infarction. Moreover, an early increase in progesterone concentration, as well as a high progesterone/estradiol ratio with less expansion in plasma volume from weeks 14 to 17 until term, may be of concern in the development of preeclampsia. 8 Women who received iron supplementation had no higher rate of adverse outcome events in our trial. Although correction of iron deficiency in pregnancy-which is a common cause of anemia in developing countries-can produce a significant increase in hemoglobin concentrations, it does not increase hemoglobin higher than the optimal concentration needed for oxygen delivery. 22 Therefore, iron supplementation is not likely a cofactor for higher hemoglobin concentrations in patients with adverse outcome events during pregnancy.
In most developing countries, anemia is a leading cause (or symptom) in women with adverse outcome events during pregnancy. Such low hemoglobin concentrations in pregnant women often are the consequence of common environmental influences and conditions 23 (eg, malnutrition, comorbidity, injury, or inadequate management of bleeding complications), which themselves potentially interfere with the normal outcome of pregnancy. Apart from very low hemoglobin concentrations (<7.0 g/dL), a number of trials found an association between anemia (<11.0 g/dL) and adverse pregnancy outcomes, whereas other studies could not confirm such an association. [24] [25] [26] Although our trial does not contribute to understanding the role of high hemoglobin and development of adverse outcome events during pregnancy, our results demonstrate that hemoglobin is an important determinant for the risk calculation of such complications and preeclampsia in particular.
ROC plots revealed rather low sensitivity and specificity of ranked single hemoglobin values for the prediction of adverse outcome events-even for the diagnosis of preeclampsia. However, approximately one third of patients with a complicated pregnancy compared with only 10% of normal pregnancies had mean hemoglobin concentrations greater than 13.0 g/dL during the second trimester; thus, in this subgroup of pregnancies, high hemoglobin is at least a cofactor for an increased risk of complicated pregnancies. In contrast, the rate of normal pregnancy outcomes was highest with mean hemoglobin values during the second trimester between 11.0 and 12.0 g/dL (40%). The frequency of complicated as well as uneventful pregnancies was not different with values below this range (apart from early birth rate), and therefore such hemoglobin concentrations signal optimal outcome rate in women of this trial. Although the hemoglobin increase during the third trimester and near term has also been shown to correlate with the rate of poor maternal and fetal outcome, this is of little concern with respect to the therapeutic options. 27 From a clinical point of view, it seems mandatory to monitor these women carefully and more frequently, especially for the development of preeclampsia, whereas hemodilution therapy has been a successful approach for prolongation of pregnancy. 28 
